Zadravec Zaletel Lorna, Kos Gregor
Radiotherapy Department, Institute of Oncology Ljubljana, Zaloška 2, Ljubljana, Slovenia.
Faculty of medicine, University of Ljubljana, Vrazov trg 2, Ljubljana, Slovenia.
J Cancer Surviv. 2022 Apr;16(2):455-460. doi: 10.1007/s11764-021-01040-8. Epub 2021 Apr 12.
To report on findings in screening colonoscopies in long-term survivors of childhood cancer treated with abdominopelvic irradiation (RT).
Screening colonoscopies were introduced at the Slovenian outpatient follow-up clinic in 2015, according to the Children's Oncology Group guidelines. In January 2019, 54 patients who received abdominopelvic irradiation for Hodgkin disease, Wilms tumour or dysgerminoma at the age of 0-16 between 1968 and 1995 were eligible for screening colonoscopy, and until December 2019, twenty-eight asymptomatic patients have undergone this examination.
Patients were 1-16 (median 13) years old at cancer diagnosis and had colonoscopy 24-47 (median 36) years after diagnosis. They received abdominopelvic irradiation with the dose 16-46 (median 30) Gy. Adenomatous lesions were found in 18 patients (64%) and advanced adenomatous lesions in one-third. Patients who received abdominopelvic RT with a dose below 30 Gy had 75% incidence of adenomatous lesions and in those who received a dose of 30 Gy or more the incidence was 60%. Alkylating agents did not have impact on this incidence.
In this first population-based study of screening colonoscopies in asymptomatic survivors of childhood cancer, we provided new evidence for 64% incidence of adenomatous lesions after abdominopelvic RT with the dose above or below 30 Gy.
Screening colonoscopies are of vital importance in patients treated with abdominal RT in childhood.
报告接受腹盆腔放疗(RT)的儿童癌症长期幸存者在结肠镜筛查中的发现。
根据儿童肿瘤学组的指南,2015年在斯洛文尼亚门诊随访诊所引入了结肠镜筛查。2019年1月,54例在1968年至1995年期间0至16岁时因霍奇金病、肾母细胞瘤或无性细胞瘤接受腹盆腔放疗的患者符合结肠镜筛查条件,截至2019年12月,28例无症状患者接受了此项检查。
患者确诊癌症时年龄为1至16岁(中位年龄13岁),确诊后24至47年(中位年龄36岁)接受了结肠镜检查。他们接受的腹盆腔放疗剂量为16至46 Gy(中位剂量30 Gy)。18例患者(64%)发现腺瘤性病变,其中三分之一为高级别腺瘤性病变。接受低于30 Gy腹盆腔放疗的患者腺瘤性病变发生率为75%,接受30 Gy或更高剂量放疗的患者发生率为60%。烷化剂对该发生率无影响。
在这项关于无症状儿童癌症幸存者结肠镜筛查的首次基于人群的研究中,我们提供了新的证据,表明接受30 Gy及以上或以下剂量腹盆腔放疗后腺瘤性病变发生率为64%。
结肠镜筛查对儿童期接受腹部放疗的患者至关重要。